Advances in Cancer Research

Erscheinungsjahr 2014
ISBN: 978-0-12-800249-0
Verlag: William Andrew Publishing

Buch, Englisch, 426 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 860 g

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.

Autoren/Hrsg.

Tew, Kenneth D.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung

Inhaltsverzeichnis

1. Glial Progenitors as Targets for Transformation in Glioma2. Therapeutic Cancer Vaccines 3. IKK/Nuclear Factor-kappaB and Oncogenesis: Roles in Tumor Initiating Cells and in the Tumor Microenvironment4. The Rb-E2F Transcriptional Regulatory Pathway in Tumor Angiogenesis and Metastasis5. ATP-Dependent Chromatin Remodeling Complexes as Novel Targets for Cancer Therapy6. Diffuse Intrinsic Pontine Gliomas: Treatments and Controversies7. In Vivo Modeling of Malignant Glioma: The Road to Effective Therapy8. Genetically Engineered Mice as Experimental Tools to Dissect the Critical Events in Breast Cancer9. Life is Three-Dimensional - As in vitro Cancer Cultures Should be

Über Autor(innen)

Tew, Kenneth D.
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.